BR112014016562A8 - estrutura de oligo-rna de dupla hélice, nanopartícula e método de preparação - Google Patents

estrutura de oligo-rna de dupla hélice, nanopartícula e método de preparação

Info

Publication number
BR112014016562A8
BR112014016562A8 BR112014016562A BR112014016562A BR112014016562A8 BR 112014016562 A8 BR112014016562 A8 BR 112014016562A8 BR 112014016562 A BR112014016562 A BR 112014016562A BR 112014016562 A BR112014016562 A BR 112014016562A BR 112014016562 A8 BR112014016562 A8 BR 112014016562A8
Authority
BR
Brazil
Prior art keywords
double
rna
stranded oligo
nanoparticle
oligo
Prior art date
Application number
BR112014016562A
Other languages
English (en)
Other versions
BR112014016562A2 (pt
BR112014016562B1 (pt
Inventor
Han Boram
Oh Park Han
Kim Han-Na
CHAE Jeiwook
Original Assignee
Bioneer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioneer Corp filed Critical Bioneer Corp
Publication of BR112014016562A2 publication Critical patent/BR112014016562A2/pt
Publication of BR112014016562A8 publication Critical patent/BR112014016562A8/pt
Publication of BR112014016562B1 publication Critical patent/BR112014016562B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/30—Production chemically synthesised

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

resumo estrutura de oligo-rna de dupla hélice, nanopartícula e método de preparação em que um composto polimérico é covalentemente ligado a um oligo-rna de fita dupla a fim de melhorar a estabilidade in vivo e a eficiência de liberação celular do oligo-rna de fita dupla, e método para preparar o mesmo. a estrutura de oligo-rna de fita dupla da invenção efetivamente melhora a estabilidade e a permeabilidade de membrana celular do oligo-rna de fita dupla, de modo que o oligo-rna de fita dupla pode ser liberado na célula mesmo em dosagem de concentração baixa para ser usado para tratar o câncer, doenças infecciosas, e similares. 1/1
BR112014016562-9A 2012-01-05 2013-01-04 Estrutura de oligo-rna de dupla hélice, nanopartícula e método de preparação BR112014016562B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2012-0001711 2012-01-05
KR20120001711 2012-01-05
PCT/KR2013/000035 WO2013103249A1 (ko) 2012-01-05 2013-01-04 고효율 나노입자형 이중나선 올리고 rna 구조체 및 그의 제조방법

Publications (3)

Publication Number Publication Date
BR112014016562A2 BR112014016562A2 (pt) 2017-06-13
BR112014016562A8 true BR112014016562A8 (pt) 2017-07-04
BR112014016562B1 BR112014016562B1 (pt) 2021-08-10

Family

ID=48745281

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014016562-9A BR112014016562B1 (pt) 2012-01-05 2013-01-04 Estrutura de oligo-rna de dupla hélice, nanopartícula e método de preparação

Country Status (10)

Country Link
US (1) US9326941B2 (pt)
EP (1) EP2801615A4 (pt)
JP (1) JP6060178B2 (pt)
KR (1) KR101752812B1 (pt)
CN (2) CN104114704A (pt)
AU (1) AU2013206989B2 (pt)
BR (1) BR112014016562B1 (pt)
CA (1) CA2860527C (pt)
RU (1) RU2577227C1 (pt)
WO (1) WO2013103249A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2796150B1 (en) * 2011-12-15 2021-02-24 Bioneer Corporation Novel oligonucleotide conjugates and use thereof
US10030243B2 (en) 2013-07-05 2018-07-24 Bioneer Corporation Nanoparticle type oligonucleotide structure having high efficiency and method for preparing same
CA2917318A1 (en) 2013-07-05 2015-01-08 Bioneer Corporation Dengue virus related genes-specific sirna, double-stranded oligo rna molecules comprising the sirna, and composition for the inhibition of dengue virus replication comprising the same
AU2014284836B2 (en) * 2013-07-05 2017-07-27 Bioneer Corporation Respiratory disease-related gene specific siRNA, double-helical oligo RNA structure containing siRNA, compositon containing same for preventing or treating respiratory disease
WO2015152693A2 (ko) 2014-04-04 2015-10-08 (주)바이오니아 신규 이중 나선 올리고 rna 및 이를 포함하는 섬유증 또는 호흡기 질환의 예방 또는 치료용 약학조성물
CA3003267A1 (en) * 2015-10-26 2017-05-04 Translate Bio Ma, Inc. Nanoparticle formulations for delivery of nucleic acid complexes
KR101861738B1 (ko) * 2016-08-24 2018-05-29 (주)바이오니아 마이크로 rna를 포함하는 이중나선 올리고 rna 구조체
US10597438B2 (en) 2016-12-14 2020-03-24 Janssen Biotech, Inc. PD-L1 binding fibronectin type III domains
US10611823B2 (en) 2016-12-14 2020-04-07 Hanssen Biotech, Inc CD137 binding fibronectin type III domains
KR102568559B1 (ko) 2016-12-14 2023-08-18 얀센 바이오테크 인코포레이티드 Cd8a-결합 섬유결합소 iii형 도메인
NL2021258B1 (en) 2018-06-14 2019-12-20 Illumina Inc Device for luminescent imaging
US11781138B2 (en) 2019-10-14 2023-10-10 Aro Biotherapeutics Company FN3 domain-siRNA conjugates and uses thereof
EP4045061A4 (en) 2019-10-14 2024-04-17 Aro Biotherapeutics Company FIBRONECTIN TYPE III DOMAINS BINDING TO CD137
CN114480377A (zh) * 2022-01-27 2022-05-13 浙江浥眸生物科技有限公司 一种刷状核酸组装体和复合纳米粒子及其应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6005087A (en) 1995-06-06 1999-12-21 Isis Pharmaceuticals, Inc. 2'-modified oligonucleotides
US5660985A (en) 1990-06-11 1997-08-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands containing modified nucleotides
US5386023A (en) 1990-07-27 1995-01-31 Isis Pharmaceuticals Backbone modified oligonucleotide analogs and preparation thereof through reductive coupling
US6221959B1 (en) * 1994-11-18 2001-04-24 Supratek Pharma, Inc. Polynucleotide compositions
US6277967B1 (en) * 1998-07-14 2001-08-21 Isis Pharmaceuticals, Inc. Carbohydrate or 2′-modified oligonucleotides having alternating internucleoside linkages
US6175001B1 (en) 1998-10-16 2001-01-16 The Scripps Research Institute Functionalized pyrimidine nucleosides and nucleotides and DNA's incorporating same
US7700760B2 (en) * 2002-02-20 2010-04-20 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular cell adhesion molecule (VCAM) gene expression using short interfering nucleic acid (siNA)
US8969543B2 (en) 2003-04-03 2015-03-03 Bioneer Corporation SiRNA-hydrophilic polymer conjugates for intracellular delivery of siRNA and method thereof
AU2003219576A1 (en) * 2003-04-03 2004-10-25 Korea Advanced Institute Of Science And Technology Conjugate for gene transfer comprising oligonucleotide and hydrophilic polymer, polyelectrolyte complex micelles formed from the conjugate, and methods for preparation thereof
JP4635046B2 (ja) * 2004-04-20 2011-02-16 マリナ・バイオテック・インコーポレーテッド 哺乳類の細胞における遺伝子発現を調節するための、二本鎖ｒｎａまたは二本鎖ハイブリッド核酸の送達を増強するための方法および組成物
RU2434942C2 (ru) * 2004-09-28 2011-11-27 Кварк Фармасьютикалс, Инк. Олигорибонуклеотиды и способы их применения для лечения острой почечной недостаточности и других заболеваний
CA2619533C (en) * 2005-08-17 2014-02-04 Bioneer Corporation Sirna-hydrophilic polymer conjugates for intracellular delivery of sirna and method thereof
JP2010501188A (ja) 2006-08-24 2010-01-21 アルコン リサーチ， リミテッド ＩＯＰに関連した病態の処置のためのグレムリンのＲＮＡｉ媒介阻害
EP2205740A2 (en) * 2007-10-02 2010-07-14 Rxi Pharmaceuticals Corp. Tripartite rnai constructs
WO2010074540A2 (ko) * 2008-12-26 2010-07-01 주식회사 삼양사 음이온성 약물 함유 약제학적 조성물 및 그 제조방법
KR101224828B1 (ko) * 2009-05-14 2013-01-22 (주)바이오니아 ｓｉＲＮＡ 접합체 및 그 제조방법
US20120225129A1 (en) 2010-08-20 2012-09-06 Cerulean Pharma Inc. Conjugates, particles, compositions, and related methods
EP2796150B1 (en) * 2011-12-15 2021-02-24 Bioneer Corporation Novel oligonucleotide conjugates and use thereof
US9649388B2 (en) * 2012-01-18 2017-05-16 Bioneer Corporation Magnetic nanoparticle-samirna complex and method for preparing same

Also Published As

Publication number Publication date
CA2860527C (en) 2019-04-09
KR101752812B1 (ko) 2017-06-30
RU2577227C1 (ru) 2016-03-10
EP2801615A4 (en) 2015-08-19
CN104114704A (zh) 2014-10-22
JP6060178B2 (ja) 2017-01-18
US20150005364A1 (en) 2015-01-01
US9326941B2 (en) 2016-05-03
BR112014016562A2 (pt) 2017-06-13
AU2013206989A1 (en) 2014-07-24
JP2015508998A (ja) 2015-03-26
KR20140109927A (ko) 2014-09-16
AU2013206989B2 (en) 2015-05-28
CN107988227A (zh) 2018-05-04
EP2801615A1 (en) 2014-11-12
CA2860527A1 (en) 2013-07-11
WO2013103249A1 (ko) 2013-07-11
BR112014016562B1 (pt) 2021-08-10

Similar Documents

Publication Publication Date Title
BR112014016562A2 (pt) estrutura de oligo-rna de dupla hélice, nanopartícula e método de preparação
MX2021001867A (es) Administracion y monitoreo de oxidio nitrico en fluidos ex vivo.
UY33396A (es) 5-fluoro-1h-pirazolopiridinas sustituidas y su uso
BR112014032809A2 (pt) melhora de autofagia ou aumento de longevidade pela administração de urolitinas ou precursores das mesmas
BR112015008186A2 (pt) formulação de um anticorpo estável e de baixa viscosidade
BR112015016997A2 (pt) composto, composição farmacêutica e método para o tratamento ou prevenção de câncer de mama
BR112015007292A2 (pt) tubulação conectora médica sobremoldada e método
BR112015006790A2 (pt) composição de cetoprofeno tópico
NI201300112A (es) Composición que comprende aflibercept, ácido folínico, 5 - fluorouracilo (5 - fu) e irinotecano ( folfiri).
CL2013002033A1 (es) Preparacion oral de desintegracion rapida que comprende granulos que comprenden un medicamento, un agente de desintegracion, un aglutinador, un agente de enmascaramiento y un agente de solubilizacion; metodo de preparacion; su uso para la profilaxis y/o tratamiento de un padecimiento bipolar.
AR090258A1 (es) Aplicacion de tintes fluorescentes para rastrear y cuantificar la dosificacion de elementos quimicos en el agua de desecho industrial
CO7151496A2 (es) Agentes terapeúticos para administración subcutánea optimizados
CL2013002585A1 (es) Cierre para un recipiente contenedor de un producto, comprendiendo el cierre de un elemento de metraial polimerico que comprende un agente de liberacion de oxidante cuya cantidad esta en una relacion porcentual en peso(0,01%-10%) dw pwso del elemeto de matreila polimerico; y procedimiento asociado.
CO7240370A2 (es) Forma farmaceútica para la liberación prolongada de sustancias activas
UY35360A (es) Imidazopiridazinas sustituidas
DOP2016000118A (es) Tienopirimidinas como inhibidores mknk1 y mknk2
CL2012003488A1 (es) Formulación intravenosa que comprende una solución acuosa de sulfobutil-eter-beta-ciclodextrina y amiodarona o una sal en proporción entre 2,7: 1 a 7:1; metodo de preparación; un artículo manufacturado, util en arritmias.
DOP2016000007A (es) Pirazolpiridinas sustituidas
BR112012033806A2 (pt) composição na forma de uma partícula, método para sua preparação e uso da composição
CL2009000844A1 (es) Metodo para tratar cancer en un paciente que comprende la administracion de un primer agente que es inhibidor de factor de crecimiento de hepatocito (hgf) en combinacion con un segundo agente que es agonista de pten.
BR112016029012A2 (pt) método de tratamento de câncer de pulmão de células não pequenas e/ou câncer de pulmão de células pequenas usando compostos de tienotriazolodiazepina
UY35735A (es) Trifluorometilpirimidinonas disustituidas y su uso
BR112015001640A2 (pt) formulações e métodos de produção de formulações para uso em evacuação colônica
UY35771A (es) Tienouracil-carboxamidas cíclicas y su uso
AR097596A1 (es) Proceso para preparar celulosa

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 04/01/2013, OBSERVADAS AS CONDICOES LEGAIS.